Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

767

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
SchizophreniaImpaired Cognition
Interventions
DRUG

EVP-6124

Arms 1, 2

DRUG

Placebo

Arm 3

Trial Locations (106)

Unknown

Phoenixville

Little Rock

Cerritos

Chino

Costa Mesa

Garden Grove

Glendale

Norwalk

Oakland

Oakland Park

Oceanside

Riverside

San Diego

San Gabriel

Santa Ana

Sherman Oaks

Washington D.C.

Bradenton

Miami

Miami Springs

North Miami

Orlando

Marietta

Smyrna

Chicago

Oak Brook

Oak Park

Wichita

Lake Charles

Shreveport

Rockville

Boston

Saint Charles

St Louis

Lincoln

Princeton

Jamaica

New York

Rochester

Charlotte

Beachwood

Oklahoma City

Jenkintown

Austin

Dallas

Salt Lake City

Bellevue

Richland

Spokane

Banfield

Caba

Mendoza

Rosario

Santiago del Estero

Adelaide

Mount Claremont

Salvader

Belo Horizonte

Curitiba

Medellín

Barranquilla

Pereira

Bogota D.C.

Florence

Milan

Ban

Barl

Catania

Lucca

Milan

Pisa

Roma

Monterrey

Mexico City

San Luis Potosí City

Bełchatów

Chełmno

Karakow

Kielce

Kotarbinskiego

Sosnowiec

Torun

Wroclaw

Campulung Muscel

Oradea

Cluj-Napoca

Palazu Mare

Iași

Târgu Mureş

Bucharest

Saint Petersburg

Smolensk

Moscow

Samara

Yaroslavl

Vil. Stepanivka

Dnipropetrovsk

Kharkiv

Kyiv

Lviv

Poltava

Vinnytsia

Cambridge

Newcastle upon Tyne

Exeter

London

All Listed Sponsors
collaborator

Syneos Health

OTHER

collaborator

NeuroCog Trials, Inc.

INDUSTRY

lead

FORUM Pharmaceuticals Inc

INDUSTRY